Published in J Virol on October 01, 1990
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med (2005) 4.68
Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J Virol (1994) 3.70
Multiplex detection of four pathogenic retroviruses using molecular beacons. Proc Natl Acad Sci U S A (1999) 3.10
Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4. J Virol (1992) 2.59
Role of CD4 endocytosis in human immunodeficiency virus infection. J Virol (1995) 1.53
Rev-dependent indicator T cell line. Curr HIV Res (2007) 1.36
A broad range of chemokine receptors are used by primary isolates of human immunodeficiency virus type 2 as coreceptors with CD4. J Virol (1998) 1.35
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob Agents Chemother (2006) 1.25
Cleavage of human immunodeficiency virus type 1 proteinase from the N-terminally adjacent p6* protein is essential for efficient Gag polyprotein processing and viral infectivity. J Virol (1998) 1.25
Inducible and conditional inhibition of human immunodeficiency virus proviral expression by vesicular stomatitis virus matrix protein. J Virol (1995) 1.21
Cytopathic variants of an attenuated isolate of human immunodeficiency virus type 2 exhibit increased affinity for CD4. J Virol (1991) 1.20
Nef proteins from diverse groups of primate lentiviruses downmodulate CXCR4 to inhibit migration to the chemokine stromal derived factor 1. J Virol (2005) 1.20
Lv2, a novel postentry restriction, is mediated by both capsid and envelope. J Virol (2004) 1.16
Cytopathicity of human immunodeficiency virus type 2 (HIV-2) in human lymphoid tissue is coreceptor dependent and comparable to that of HIV-1. J Virol (2000) 1.04
Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein. J Virol (1996) 0.98
Characterization of a late entry event in the replication cycle of human immunodeficiency virus type 2. J Virol (2001) 0.94
HIV-2 genetic evolution in patients with advanced disease is faster than that in matched HIV-1 patients. J Virol (2010) 0.93
Dendritic cells are less susceptible to human immunodeficiency virus type 2 (HIV-2) infection than to HIV-1 infection. J Virol (2007) 0.92
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV. Antimicrob Agents Chemother (2010) 0.90
Development of real-time PCR array for simultaneous detection of eight human blood-borne viral pathogens. PLoS One (2012) 0.88
Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2. Antimicrob Agents Chemother (2008) 0.87
New sensitive one-step real-time duplex PCR method for group A and B HIV-2 RNA load. J Clin Microbiol (2014) 0.86
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir. Antimicrob Agents Chemother (2007) 0.86
Mortality among human immunodeficiency virus type 2-positive villagers in rural Guinea-Bissau is correlated with viral genotype. J Virol (1998) 0.85
Proviral progeny of heterodimeric virions reveal a high crossover rate for human immunodeficiency virus type 2. J Virol (2006) 0.77
In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother (2013) 0.76
Single-Strand Consensus Sequencing Reveals that HIV Type but not Subtype Significantly Impacts Viral Mutation Frequencies and Spectra. J Mol Biol (2017) 0.75
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science (1988) 220.77
Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol (1967) 106.91
Genome organization and transactivation of the human immunodeficiency virus type 2. Nature (1987) 11.79
An improved method for directly sequencing PCR amplified material using dimethyl sulphoxide. Nucleic Acids Res (1989) 10.50
Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol (1989) 8.32
Isolation of a new human retrovirus from West African patients with AIDS. Science (1986) 7.97
Sequence of simian immunodeficiency virus from macaque and its relationship to other human and simian retroviruses. Nature (1987) 7.96
Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet (1986) 7.09
HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions. J Acquir Immune Defic Syndr (1989) 6.16
Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions. Virology (1985) 6.08
Variable and conserved neutralization antigens of human immunodeficiency virus. Nature (1987) 5.29
An African primate lentivirus (SIVsm) closely related to HIV-2. Nature (1989) 5.03
SIV adaptation to human cells. Nature (1989) 3.09
Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization. Proc Natl Acad Sci U S A (1988) 2.37
Prevalence of and mortality from human immunodeficiency virus type 2 in Bissau, West Africa. Lancet (1989) 2.33
Human immunodeficiency virus type 2 infection associated with AIDS in West Africa. N Engl J Med (1987) 2.32
Human immunodeficiency virus infection of monocytic and T-lymphocytic cells: receptor modulation and differentiation induced by phorbol ester. Virology (1987) 2.30
Genetic variability between isolates of human immunodeficiency virus (HIV) type 2 is comparable to the variability among HIV type 1. Proc Natl Acad Sci U S A (1988) 2.07
A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope. Proc Natl Acad Sci U S A (1987) 1.87
West African HIV-2-related human retrovirus with attenuated cytopathicity. Science (1988) 1.86
A new human retrovirus isolate of West African origin (SBL-6669) and its relationship to HTLV-IV, LAV-II, and HTLV-IIIB. AIDS Res Hum Retroviruses (1987) 1.67
Clinical, hematologic, and immunologic cross-sectional evaluation of individuals exposed to human immunodeficiency virus type-2 (HIV-2). AIDS Res Hum Retroviruses (1988) 1.58
Lymphadenopathy-associated virus type 2 in AIDS and AIDS-related complex. Clinical and virological features in four patients. Lancet (1987) 1.49
Molecular and biological characterization of a replication competent human immunodeficiency type 2 (HIV-2) proviral clone. Proc Natl Acad Sci U S A (1989) 1.48
A highly divergent HIV-2-related isolate. Nature (1990) 1.45
Origin of the HIV-susceptible human CD4+ cell line H9. AIDS Res Hum Retroviruses (1989) 1.45
Molecular cloning of two west African human immunodeficiency virus type 2 isolates that replicate well in macrophages: a Gambian isolate, from a patient with neurologic acquired immunodeficiency syndrome, and a highly divergent Ghanian isolate. Proc Natl Acad Sci U S A (1989) 1.40
Evaluation of human and simian immunodeficiency virus plaque and neutralization assays. J Gen Virol (1989) 1.39
HIV-2 infection in two homosexual men in France. Lancet (1987) 1.27
Characterization of an HIV-2-related virus with a smaller sized extracellular envelope glycoprotein. Virology (1989) 1.20
Genomic divergence of HIV-2 from Ghana. AIDS Res Hum Retroviruses (1989) 1.20
HIV-2 antisera cross-neutralize HIV-1. AIDS (1988) 1.17
HIV-2 link to AIDS in West Africa. J Acquir Immune Defic Syndr (1990) 1.13
Envelope cross-reactivity in Western blot for HIV-1 and HIV-2 may not indicate dual infection. Lancet (1988) 1.11
Six new isolates of human immunodeficiency virus type 2 (HIV-2) and the molecular characterization of one (HIV-2CAM2). J Gen Virol (1989) 1.01
Replicative and cytopathic characteristics of HIV-2 and severity of infection. Lancet (1989) 0.94
No clinical signs 14 years after HIV-2 transmission via blood transfusion. Lancet (1988) 0.90
Recombinant peptides derived from the env-gene of HIV-2 in the serodiagnosis of HIV-2 infections. AIDS (1989) 0.87
Cross-neutralizing antibodies against HIV-1 (HTLV-IIIB and HTLV-IIIRF) and HIV-2 (SBL-6669 and a new isolate SBL-K135). AIDS Res Hum Retroviruses (1989) 0.84
Origin of HIV. BMJ (1989) 0.79
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (1985) 30.47
The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell (1986) 22.26
Laser capture microdissection. Science (1996) 12.21
Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science (1990) 10.13
Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med (1995) 6.71
Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature (1985) 6.65
Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science (1996) 6.57
Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N Engl J Med (1998) 6.14
Infection of human cells by an endogenous retrovirus of pigs. Nat Med (1997) 5.71
A new classification for HIV-1. Nature (1998) 5.30
Variable and conserved neutralization antigens of human immunodeficiency virus. Nature (1987) 5.29
HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med (1995) 5.22
Prevalence of antibody to human T-lymphotropic virus type III in AIDS and AIDS-risk patients in Britain. Lancet (1984) 5.20
High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol (1995) 4.59
Genetic recombinants and heterozygotes derived from endogenous and exogenous avian RNA tumor viruses. Virology (1973) 4.56
Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A (1999) 4.52
Epitopes of the CD4 antigen and HIV infection. Science (1986) 4.50
Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J Virol (1996) 4.43
The CD4 antigen: physiological ligand and HIV receptor. Cell (1988) 4.42
HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood (2000) 4.22
Receptor interference groups of 20 retroviruses plating on human cells. Virology (1990) 4.15
Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet (1996) 4.05
Monoclonal antibody analysis of keratin expression in epidermal diseases: a 48- and 56-kdalton keratin as molecular markers for hyperproliferative keratinocytes. J Cell Biol (1984) 4.00
Human immunodeficiency virus infection of CD4-bearing cells occurs by a pH-independent mechanism. EMBO J (1988) 3.98
Characterization of HIV-1 neutralization escape mutants. AIDS (1989) 3.88
Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1. Nature (1983) 3.86
Identification of the residues in human CD4 critical for the binding of HIV. Cell (1989) 3.71
Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science (1997) 3.70
The pH independence of mammalian retrovirus infection. J Gen Virol (1990) 3.68
Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by Simian immunodeficiency virus. Virology (1991) 3.54
Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature (1989) 3.54
Limited transmission of Kaposi's sarcoma-associated herpesvirus in cultured cells. J Virol (1998) 3.54
Virus infection of murine teratocarcinoma stem cell lines. Cell (1977) 3.54
Cyclin encoded by KS herpesvirus. Nature (1996) 3.32
Detection of avian tumor virus-specific nucleotide sequences in avian cell DNAs (reassociation kinetics-RNA tumor viruses-gas antigen-Rous sarcoma virus, chick cells). Proc Natl Acad Sci U S A (1972) 3.28
Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries. BMJ (1995) 3.21
Neutralizing monoclonal antibodies to the AIDS virus. AIDS (1988) 3.06
Mobility and the spread of human immunodeficiency virus into rural areas of West Africa. Int J Epidemiol (2003) 3.06
An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature (1989) 3.01
Induction of avian tumor viruses in normal cells by physical and chemical carcinogens. Virology (1971) 3.00
Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guérin vaccination. J Immunol (1999) 2.94
Host range and interference studies of three classes of pig endogenous retrovirus. J Virol (1998) 2.94
A novel lymphotropic herpesvirus. Lancet (1987) 2.89
HIV infection does not require endocytosis of its receptor, CD4. Cell (1988) 2.88
HIV infection and neoplasia. Lancet (1996) 2.83
Feline leukemia virus subgroup B uses the same cell surface receptor as gibbon ape leukemia virus. J Virol (1992) 2.80
Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. J Infect Dis (1999) 2.79
Kaposi's-sarcoma-associated herpesvirus in HIV-negative Kaposi's sarcoma. Lancet (1995) 2.74
Two sets of human-tropic pig retrovirus. Nature (1997) 2.74
The etiology of pneumonia in malnourished and well-nourished Gambian children. Pediatr Infect Dis J (1994) 2.73
Antibodies against human herpesvirus 8 in black South African patients with cancer. N Engl J Med (1999) 2.63
Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4. J Virol (1992) 2.59
KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway. Oncogene (1997) 2.57
Randomised trial of effect of vitamin A supplementation on antibody response to measles vaccine in Guinea-Bissau, west Africa. Lancet (1997) 2.50
Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4. AIDS (1990) 2.46
A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism. J Virol (1993) 2.46
Genetic susceptibility to tuberculosis in Africans: a genome-wide scan. Proc Natl Acad Sci U S A (2000) 2.44
Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol (1995) 2.36
Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol (1994) 2.36
Risk factors for transmission of hepatitis B virus to Gambian children. Lancet (1990) 2.35
The human and simian immunodeficiency viruses HIV-1, HIV-2 and SIV interact with similar epitopes on their cellular receptor, the CD4 molecule. AIDS (1988) 2.35
Human immunodeficiency virus infection in two cohorts of homosexual men: neutralising sera and association of anti-gag antibody with prognosis. Lancet (1987) 2.34
Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120. Proc Natl Acad Sci U S A (1988) 2.34
Kaposi's sarcoma-associated herpesvirus and Kaposi's sarcoma in Africa. Uganda Kaposi's Sarcoma Study Group. Arch Intern Med (1996) 2.33
Pediatric Vesicoureteral Reflux Guidelines Panel summary report on the management of primary vesicoureteral reflux in children. J Urol (1997) 2.32
No evidence of pig DNA or retroviral infection in patients with short-term extracorporeal connection to pig kidneys. Lancet (1998) 2.32
Human immunodeficiency virus infection of monocytic and T-lymphocytic cells: receptor modulation and differentiation induced by phorbol ester. Virology (1987) 2.30
DNA in medicine. Oncogenes. Lancet (1984) 2.28
Productive infection and cell-free transmission of human T-cell leukemia virus in a nonlymphoid cell line. Science (1983) 2.26
Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia. AIDS (2000) 2.26
The cyclin encoded by Kaposi's sarcoma-associated herpesvirus stimulates cdk6 to phosphorylate the retinoblastoma protein and histone H1. J Virol (1997) 2.24
Human herpesvirus 8 seroprevalence in blood donors and lymphoma patients from different regions of Italy. J Natl Cancer Inst (1998) 2.23
Transcriptional analysis of human herpesvirus-8 open reading frames 71, 72, 73, K14, and 74 in a primary effusion lymphoma cell line. Virology (1999) 2.23
Detection of human herpesvirus 8 DNA in semen from HIV-infected individuals but not healthy semen donors. AIDS (1997) 2.20
Human herpesvirus 8 in Brazilian Amerindians: a hyperendemic population with a new subtype. J Infect Dis (2000) 2.18
Food intake increases liver stiffness measurements and hampers reliable values in patients with chronic hepatitis B and healthy controls: the PROLIFICA experience in The Gambia. Aliment Pharmacol Ther (2013) 2.13
Role of schools in the transmission of measles in rural Senegal: implications for measles control in developing countries. Am J Epidemiol (1999) 2.12
Identification of a major latent nuclear antigen, LNA-1, in the human herpesvirus 8 genome. J Hum Virol (1999) 2.09
Long-term survival after Edmonston-Zagreb measles vaccination in Guinea-Bissau: increased female mortality rate. J Pediatr (1993) 2.08
Human T-lymphotropic virus type III (HTLV-III) infection in seronegative haemophiliacs after transfusion of factor VIII. Lancet (1985) 2.08
Human T-cell leukemia virus type I: induction of syncytia and inhibition by patients' sera. Int J Cancer (1983) 2.08
Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide. Virology (1988) 2.05
Decline in measles case fatality ratio after the introduction of measles immunization in rural Senegal. Am J Epidemiol (1997) 1.99
Establishing a KSHV+ cell line (BCP-1) from peripheral blood and characterizing its growth in Nod/SCID mice. Blood (1998) 1.95
Host gene control of endogenous avian leukosis virus production. Virology (1974) 1.94
Morphological and biochemical characterization of viral particles produced by the tsO45 mutant of vesicular stomatitis virus at restrictive temperature. J Virol (1979) 1.93
Processing of the Plasmodium falciparum major merozoite surface protein-1: identification of a 33-kilodalton secondary processing product which is shed prior to erythrocyte invasion. Mol Biochem Parasitol (1991) 1.92
Kaposi's sarcoma in the Gambia, West Africa is less frequent in human immunodeficiency virus type 2 than in human immunodeficiency virus type 1 infection despite a high prevalence of human herpesvirus 8. J Hum Virol (1999) 1.90
Human T cell leukemia viruses use a receptor determined by human chromosome 17. Science (1988) 1.87